New hope for rare blood cancers: targeted drug trial opens

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Age ≥ 18 years, with no restrictions on gender; 2. Histologically confirmed relapsed/refractory (R/R) indolent T/NK-cell; lymphoma that has failed at least one systemic therapy or is intolerant to such treatment and/or currently has no effective standard treatment options; 3. The patient meets the criteria for appropriate therapeutic indications; 4. ECOG performance status of 0-2; 5. Adequate organ function, defined as: Total bilirubin (TBIL) ≤ 1.5 × ULN; ALT and AST ≤ 2.5 × ULN; Blood urea nitrogen (BUN)/Urea and creatinine (Cr) ≤ 1.5 × ULN; Left ventricular ejection fraction (LVEF) ≥ 50%; Fridericia-corrected QT interval (QTcF): \< 450 ms for males, \< 470 ms for females; 6. An expected survival time of at least 3 months; 7. Male and female subjects of childbearing potential must agree to use effective contraception throughout the study period and for 6 months after the last dose of the investigational drug; 8. A washout period of ≥ 4 weeks since receiving any prior antitumor therapies (including radiotherapy, chemotherapy, hormone therapy, surgery, or molecular targeted therapy) before participating in this study; 9. The subject has not participated in any other clinical trial within 1 month prior to enrollment; 10. The subject agrees to and signs the informed consent form. Exclusion Criteria: 1. Subjects who have previously used any JAK inhibitors; 2. Subjects with clinical conditions such as dysphagia, malabsorption, or other chronic gastrointestinal diseases that may interfere with compliance and/or absorption of the study drug; 3. Subjects with active viral, bacterial, or fungal infections requiring treatment (e.g., pneumonia); 4. Subjects with HBV or HCV infections, defined as HBsAg and/or HBcAb positivity and HBV DNA copy number ≥ the upper limit of normal (ULN), or acute or chronic active hepatitis C (HCV antibody-positive); 5. Subjects with a history of immunodeficiency, including those who are HIV-positive, or those with other acquired or congenital immunodeficiency diseases, a history of organ transplantation, or a history of allogeneic bone marrow or hematopoietic stem cell transplantation; 6. Subjects who have undergone autologous hematopoietic stem cell transplantation within 90 days prior to the first dose of study treatment; 7. Subjects with severe or uncontrolled cardiovascular diseases; 8. Subjects with severe concomitant diseases that pose a significant risk to patient safety or, in the investigator's judgment, may interfere with the completion of the study (e.g., uncontrolled hypertension, diabetes, or thyroid disorders); 9. Pregnant or breastfeeding female subjects, or baseline positive pregnancy test results in women of childbearing potential; 10. Subjects with a history of other malignancies diagnosed or treated within the past 5 years; 11. Any other conditions that, in the investigator's opinion, render the subject unsuitable for participation in the study.